Literature DB >> 19641060

Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.

Christophe Pasquier1, Karine Sauné, Stéphanie Raymond, Nathalie Moinard, Myriam Daudin, Louis Bujan, Jacques Izopet.   

Abstract

The semen plasma virus load is measured to ensure the safety of sperm processing during medically assisted procreation (MAP) for couples with a human immunodeficiency virus type 1 (HIV-1)-infected man. A practical, automated protocol using the COBAS Ampliprep CAP/CTM kit in the COBAS TaqMan96 system was developed to measure the HIV-1 load in semen plasma samples. HIV-1 was detected in 13.4% of the semen samples processed at our MAP center. Of the eight patients having a detectable semen HIV-1 load, five had no detectable virus in their blood plasma. This highlights the residual risk of HIV-1 transmission during unprotected intercourse and raises the question of the possible consequences of ineffective highly active antiretroviral therapy in the genital tract.

Entities:  

Mesh:

Year:  2009        PMID: 19641060      PMCID: PMC2738122          DOI: 10.1128/JCM.02131-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV.

Authors:  Jesús Castilla; Jorge Del Romero; Victoria Hernando; Beatriz Marincovich; Soledad García; Carmen Rodríguez
Journal:  J Acquir Immune Defic Syndr       Date:  2005-09-01       Impact factor: 3.731

2.  Validation of an automated real-time PCR protocol for detection and quantitation of HIV and HCV genomes in semen.

Authors:  Christophe Pasquier; Corinne Souyris; Nathalie Moinard; Louis Bujan; Jacques Izopet
Journal:  J Virol Methods       Date:  2006-07-14       Impact factor: 2.014

3.  Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation.

Authors:  Christophe Pasquier; Deborah Anderson; Corinne Andreutti-Zaugg; Rianne Baume-Berkenbosch; Florence Damond; Aviva Devaux; Yvon Englert; Julie Galimand; Carole Gilling-Smith; Odile Guist'hau; Lital Hollander; Marianne Leruez-Ville; Benoit Lesage; Anne Maillard; Anne-geneviève Marcelin; Marie-Paule Schmitt; Augusto Semprini; Maria Vourliotis; Chong Xu; Louis Bujan
Journal:  J Med Virol       Date:  2006-07       Impact factor: 2.327

4.  HIV-discordant couples and parenthood: how are we dealing with the risk of transmission?

Authors:  Pietro L Vernazza; Lital Hollander; Augusto E Semprini; Deborah J Anderson; Ann Duerr
Journal:  AIDS       Date:  2006-02-28       Impact factor: 4.177

5.  Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.

Authors:  Y Sunila Reddy; S Karl Gotzkowsky; Joseph J Eron; Julie Y Kim; William D Fiske; Susan A Fiscus; Leslie Petch; Myron S Cohen; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2002-10-07       Impact factor: 5.226

6.  Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy.

Authors:  Pablo Barreiro; Jorge del Romero; Manuel Leal; Victoria Hernando; Román Asencio; Carmen de Mendoza; Pablo Labarga; Marina Núñez; José Tomás Ramos; Juan González-Lahoz; Vincent Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

7.  Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Authors:  Caroline Solas; Alain Lafeuillade; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men.

Authors:  Jade Ghosn; Jean-Paul Viard; Christine Katlama; Marta de Almeida; Roland Tubiana; Franck Letourneur; Laurent Aaron; Cécile Goujard; Dominique Salmon; Marianne Leruez-Ville; Christine Rouzioux; Marie-Laure Chaix
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

9.  Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.

Authors:  Giuseppina Liuzzi; Antonio Chirianni; Mauro Zaccarelli; Daniela Zinzi; Vincenzo Esposito; Vincenzo Guadagnino; Andrea Antinori; Marcello Piazza
Journal:  In Vivo       Date:  2004 Jul-Aug       Impact factor: 2.155

10.  Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission.

Authors:  J J Eron; P L Vernazza; D M Johnston; F Seillier-Moiseiwitsch; T M Alcorn; S A Fiscus; M S Cohen
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177

View more
  13 in total

1.  Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States.

Authors:  Angela R Bazzi; Ashley A Leech; Dea L Biancarelli; Meg Sullivan; Mari-Lynn Drainoni
Journal:  AIDS Patient Care STDS       Date:  2017-07-18       Impact factor: 5.078

Review 2.  Plausibility of HIV-1 Infection of Oral Mucosal Epithelial Cells.

Authors:  M C Herzberg; A Vacharaksa; K H Gebhard; R A Giacaman; K F Ross
Journal:  Adv Dent Res       Date:  2011-04

3.  A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.

Authors:  Mayla Hsu; Meropi Aravantinou; Radhika Menon; Samantha Seidor; Daniel Goldman; Jessica Kenney; Nina Derby; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Jose A Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

4.  Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).

Authors:  Cyril Clavel; Gilles Peytavin; Roland Tubiana; Cathia Soulié; Catherine Crenn-Hebert; Isabelle Heard; François Bissuel; Houria Ichou; Claudia Ferreira; Christine Katlama; Anne-Geneviève Marcelin; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

5.  The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques.

Authors:  R Singer; N Derby; A Rodriguez; L Kizima; J Kenney; M Aravantinou; A Chudolij; A Gettie; J Blanchard; J D Lifson; M Piatak; J A Fernández-Romero; T M Zydowsky; M Robbiani
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

Review 6.  HIV vaccines: progress to date.

Authors:  C Mee Ling Munier; Christopher R Andersen; Anthony D Kelleher
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

7.  Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.

Authors:  Sidonie Lambert-Niclot; Gilles Peytavin; Claudine Duvivier; Catherine Poirot; Michèle Algarte-Genin; Sophie Pakianather; Jean-Luc Meynard; Marc-Antoine Valantin; Jean-Michel Molina; Philippe Flandre; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

8.  Semen may harbor HIV despite effective HAART: another piece in the puzzle.

Authors:  Philippe Halfon; Claude Giorgetti; Hacène Khiri; Guillaume Pénaranda; Philippe Terriou; Géraldine Porcu-Buisson; Véronique Chabert-Orsini
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

Review 9.  AIDS vaccines and preexposure prophylaxis: is synergy possible?

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205

10.  An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques.

Authors:  Jessica Kenney; Meropi Aravantinou; Rachel Singer; Mayla Hsu; Aixa Rodriguez; Larisa Kizima; Ciby J Abraham; Radhika Menon; Samantha Seidor; Anne Chudolij; Agegnehu Gettie; James Blanchard; Jeffrey D Lifson; Michael Piatak; Jose A Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani
Journal:  PLoS One       Date:  2011-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.